Array Biopharma files new-drug applications, stock price climbs

BOULDER — Cancer-research firm Array Biopharma Inc. (Nasdaq: ARRY) filed new-drug applications with the U.S. Food and Drug Administration.

The drug applications are for the combined use of 45 milligrams of binimetinib twice a day with 450 milligrams of encroafenib once a day for the treatment of patients with advanced or metastatic melanoma.

Array filed the applications after positive results from its phase three Columbus study. That study found that patients who use that combination of drugs have a survival rate without progression of the cancer that is longer than other drugs in use.

SPONSORED CONTENT

Select your Republic Services residential cart now!

In preparation for Republic Services becoming the primary provider of residential recycling, yard trimmings, and trash, residents should now select the best cart size and service schedule for their household needs.

Array’s stock price was $8.85 per share at the time of publication, a 15-cent increase from when the market closed on July 3, prior to the news of the drug applications.